Spire Healthcare Group (LON:SPI) Posts Earnings Results
by Danessa Lincoln · The Markets DailySpire Healthcare Group (LON:SPI – Get Free Report) announced its earnings results on Wednesday. The company reported GBX (0.50) EPS for the quarter, Digital Look Earnings reports. Spire Healthcare Group had a negative return on equity of 0.26% and a negative net margin of 0.12%.
Spire Healthcare Group Stock Performance
LON SPI opened at GBX 247.50 on Friday. The firm has a market capitalization of £991.48 million, a P/E ratio of 61.88, a price-to-earnings-growth ratio of 1.06 and a beta of 0.93. The company has a current ratio of 0.58, a quick ratio of 0.73 and a debt-to-equity ratio of 180.14. The firm’s fifty day moving average price is GBX 238.59 and its two-hundred day moving average price is GBX 208.04. Spire Healthcare Group has a 1 year low of GBX 140.80 and a 1 year high of GBX 249.
Analysts Set New Price Targets
Separately, Royal Bank Of Canada cut Spire Healthcare Group to a “sector perform” rating and decreased their price objective for the company from GBX 300 to GBX 250 in a report on Monday, September 7th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of GBX 247.50.
Check Out Our Latest Stock Report on Spire Healthcare Group
Spire Healthcare Group Company Profile
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments.
Read More
- Five stocks we like better than Spire Healthcare Group
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next